ABEONA THERAPEUT. DL-01 (F:PCJ) — Market Cap & Net Worth
Market Cap & Net Worth: ABEONA THERAPEUT. DL-01 (PCJ)
ABEONA THERAPEUT. DL-01 (F:PCJ) has a market capitalization of $236.27 Million (€202.10 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #15914 globally and #1526 in its home market, demonstrating a -1.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABEONA THERAPEUT. DL-01's stock price €4.43 by its total outstanding shares 54191361 (54.19 Million).
ABEONA THERAPEUT. DL-01 Market Cap History: 2015 to 2026
ABEONA THERAPEUT. DL-01's market capitalization history from 2015 to 2026. Data shows growth from $200.14 Million to $280.92 Million (2.05% CAGR).
ABEONA THERAPEUT. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABEONA THERAPEUT. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PCJ by Market Capitalization
Companies near ABEONA THERAPEUT. DL-01 in the global market cap rankings as of May 5, 2026.
Key companies related to ABEONA THERAPEUT. DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ABEONA THERAPEUT. DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, ABEONA THERAPEUT. DL-01's market cap moved from $200.14 Million to $ 280.92 Million, with a yearly change of 2.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €280.92 Million | -4.85% |
| 2025 | €295.24 Million | -11.24% |
| 2024 | €332.62 Million | +15.89% |
| 2023 | €287.00 Million | +75.58% |
| 2022 | €163.46 Million | +891.54% |
| 2021 | €16.49 Million | -78.84% |
| 2020 | €77.90 Million | -59.02% |
| 2019 | €190.07 Million | -47.28% |
| 2018 | €360.49 Million | -57.30% |
| 2017 | €844.15 Million | +190.98% |
| 2016 | €290.10 Million | +44.95% |
| 2015 | €200.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ABEONA THERAPEUT. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $236.27 Million USD |
| MoneyControl | $236.27 Million USD |
| MarketWatch | $236.27 Million USD |
| marketcap.company | $236.27 Million USD |
| Reuters | $236.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt dise… Read more